Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius
about
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsFourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignanciesJuvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationGraft-versus-host disease: why have we not made more progress?Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAlternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaLow incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMTCurrent issues in chronic graft-versus-host disease.Failure-free survival after initial systemic treatment of chronic graft-versus-host diseaseLess graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantationAssociation of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host diseaseMulti-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningSingle-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancyLow-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.How we treat chronic graft-versus-host disease.Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMTProphylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidenceImpact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemiaUnrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the APhase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationComparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell tIn Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children.Prevention of graft-vs.-host diseasePredictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.
P2860
Q24200813-0773AA74-C2A4-4DFE-A288-AEEF43F830CAQ26830130-D6C60C7E-24AD-4409-8C1A-E86EEED45DC7Q26851000-12F00766-976B-41CB-B2AF-77D14E27F345Q27012940-9C7CFC57-2499-4F07-879D-55053BFE2B06Q27014857-D38DE9BE-9748-46E0-AFC6-9B43B2FE3AB5Q28076264-2A7C3F5F-35CD-4733-A141-76B76E018E3CQ28080943-A6216BEB-468C-4258-BE5A-E39E3766FAC6Q30252205-967A6D1C-DBF4-44F7-B4B8-B2B596241513Q33576014-D5A567BD-3374-4E34-8D91-AE3E58FC705CQ33797194-C31434DD-D6DC-43C0-A5FC-CED25B2C2D4CQ33820379-24B6388E-D6FD-43AA-AB0E-56CCE0DC4285Q33917187-6D1BBDEB-3513-43FA-99DC-0F01684D4766Q34077787-3F89485A-0D7C-446B-B7E2-CF76DDADFE0DQ34134601-02F0975E-50B7-4D60-82B7-AC7901D222B3Q34272547-0117DD06-639E-4E9E-93B7-8DA73F47FC08Q34402494-5975AEE2-AF30-4F3B-93B7-D97556BB4501Q34684038-0AF36B7D-5375-45DD-8CFC-6969A953510EQ34749391-9B7B073C-0E1F-45D9-9514-5682CCF23694Q34860077-51332DBE-4D7A-42AC-BE47-D6C49DC887DBQ35004923-94A87B6B-EC81-4651-B722-9505BDD247ADQ35038942-9D413136-5C6F-449A-AAF9-1F53991B3543Q35095722-0D7779E5-8C16-4E99-ADDD-9D690426B4C9Q35199893-0A9C29ED-40A4-4ACF-904C-FF1661340A7CQ35218515-008A90A9-BBBC-460C-A350-0E2A7DD075A3Q35561803-9196C6E2-DC2A-4481-9A7A-B4E8573A2F11Q35571058-9530C2F0-B74C-44A3-B246-C0F908E44B3BQ35670693-1A9FB4C8-E18B-4680-BDF9-14442F6C1F4AQ35934770-B6296AA7-C267-4CDB-A228-390D6A0EB137Q36036605-E360D258-FE4B-4F16-8E03-5CEF8FDDD7D9Q36057911-D0D462F9-2816-4ECA-A885-6183BB9FF20EQ36057916-9A90D337-B76C-491F-93A8-B2A45A121A30Q36125603-468453BD-E52D-40E1-8E10-FCFD7D4F23C3Q36176670-8189777E-BAD7-43BF-A051-D15D176A038EQ36212392-B3A767BA-5F6A-4B75-8913-C1A9EB4FEA87Q36264735-AEA5D7C1-09B7-4019-8C01-EC3710EA014BQ36431047-052A108A-3E80-48F8-9518-2E71AE2855EEQ36443116-2BF8F79A-3947-4A8B-96D5-AE9612D77AD5Q36637621-C126FD96-D636-4B9F-A245-143A536DAE0BQ36709850-F6D82DB4-8D2B-48E3-9F13-FB9368597E01Q36892442-99693628-E02F-49AF-864D-7BEA845F5A0C
P2860
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius
description
im April 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2011
@uk
name
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@en
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@nl
type
label
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@en
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@nl
prefLabel
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@en
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@nl
P2093
P1433
P1476
Chronic graft-versus-host dise ...... -T-cell globulin ATG-Fresenius
@en
P2093
A. R. Zander
C. Schmoor
D. A. Heim
H. D. Ottinger
H. Einsele
H.-J. Kolb
J. A. Maertens
P304
P356
10.1182/BLOOD-2011-01-329821
P407
P577
2011-04-05T00:00:00Z